Evgen Pharma Share Chat (EVG)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Evgen Pharma	LSE:EVG	London	Ordinary Share	GB00BSVYN304	ORD 0.25P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	18.75p	18.00p	19.50p	18.75p	18.75p	18.75p	0	08:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-3.6	-4.2	-	13.90

Evgen Pharma Share Discussion Threads

Showing 476 to 494 of 500 messages

Chat Pages: 20 19 18 17 16 15 14 13 12 11 10 9 Older

Date	Subject	Author	Discuss
07/10/2017 09:15	New research by University of East Anglia on the effects of Sulforaphane on liver cancer. Title: Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling From the abstract; Collectively, these findings provide new insights into the inhibitory effect of SFN on HCC tumor angiogenesis as well as tumor growth, and indicate that SFN has potential for the prevention and treatment of HCC hTTps://www.nature.com/articles/s41598-017-12855-w	pdt	Read Full Thread Reply
02/10/2017 14:46	Thanks for the link. Nothing new but a good read. I liked the quote from Stephen Franklin of his hopes for SFX-01 turning breast cancer from a death sentence to a chronic condition for women where the cancer has spread. He must have knowledge of how the compassionate use programme is going when he made that quote, I think it has been active for 3 months now. Perhaps an update with results in December. All positive though and I wonder if other publications will pick up the story.	pdt	Read Full Thread Reply
02/10/2017 09:53	Here's the link, need to register to read full article: Keep taking the broccoli, says British pharma company October 1 2017, 12:01am, The Sunday Times Https://www.thetimes.co.uk/edition/business/keep-taking-the-broccoli-says-british-pharma-company-3mdlwtx6n	martywidget	Read Full Thread Reply
02/10/2017 09:32	Apparently a mention in yesterdays Sunday Times business section. I have not seen the article, anyone know what it says?	pdt	Read Full Thread Reply
26/9/2017 11:31	Another good piece of research on Sulforaphane and breast cancer; Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells hTTp://www.thno.org/v07p3461.htm A bit disappointing that the share price is drifting lower. That will not help the inevitable fund raise. Hopefully, there will be some positive news before they complete that. I have been buying on the way down but now I have probably as many as I want to hold at this stage.	pdt	Read Full Thread Reply
04/9/2017 13:13	I wondered about those options too. Could it it a case that they are checking under the cushions of the sofa for some lost change? They are forecast to have around £268K cash left at the end of March, but that figure depends on receiving £660K in tax credit from HMRC, so maybe it was friends and family helping out by cashing the options early (they still had a long way to run) in order to give them a bit more breathing space?	timbo003	Read Full Thread Reply
03/9/2017 18:05	PDT thanks!I wondered if the options exchanged for shares were people cashing in before a fund raising	dave444	Read Full Thread Reply
03/9/2017 09:24	dave444 - the chances of a fundraising event are high over the next few months. They run out of cash mid 2018 and need to complete their two phase 2 trials ending late 2018. In a recent interview the CEO stated more funds would be needed. However, the amount needed is small, perhaps a £1m.	pdt	Read Full Thread Reply
02/9/2017 16:32	What are the chances of a fundraising event in the next few months?	dave444	Read Full Thread Reply
01/9/2017 13:41	NICE turns down AZ's Faslodex hTTp://www.pharmatimes.com/news/nice_turns_down_az_faslodex_for_breast_cancer_1203957 It will be interesting if results from the Evgen trial show that SFX-01 will routinely extend progression free survival beyond six months. We know that applies to at least one participant following the compassionate use programme announcement. Here is a quote from the above article which puts the value of such extensions in context; "According to the data from the Phase III FALCON trial, median progression-free survival (PFS) was significantly longer with Faslodex than with anastrozole, at 16.6 months versus 13.8 months" So potentially adding 6+ months to the above numbers. Still early days but certainly very encouraging.	pdt	Read Full Thread Reply
16/8/2017 20:35	More research just published by the University of Maryland school of medicine; "Combination Cisplatin and Sulforaphane Treatment Reduces Proliferation, Invasion and Tumor Formation in Epidermal Squamous Cell Carcinoma" Extract From the conclusion; "Both agents suppress tumor formation, but enhanced suppression is observed with combined treatment. Moreover, both agents reduce the number of tumor-resident cancer stem cells. SFN treatment of cultured cells or tumors increases apoptosis and p21Cip1 level, and both agents increase tumor apoptosis. We suggest that combined therapy with sulforaphane and cisplatin is efficient in suppressing tumor formation and may be a treatment option for advanced epidermal squamous cell carcinoma." hTTps://www.ncbi.nlm.nih.gov/pubmed/28796401 This must be encouraging for Evgen's Metastatic Breast Cancer study.	pdt	Read Full Thread Reply
02/8/2017 15:56	New published research on SFX-01 and Osteoarthritis "In conclusion, we report that SFX-01® improves bone microarchitecture in vivo, produces corresponding changes in bone cell behaviour in vitro to enhance indices of bone mechanical strength and produces greater symmetry in gait, without marked effects on cartilage lesion severity in STR/Ort osteoarthritic mice. Our findings support both osteotrophic roles and novel beneficial gait effects for SFX-01® that appear to be independent of articular cartilage lesion development in this model of spontaneous OA." hTTp://www.thebonejournal.com/article/S8756-3282(17)30263-6/fulltext?cc=y= I see that the work was partly funded by Arthritis Research UK And a quick search revealed that OA affects over 100m people in the US alone. The treatments all seem to be palliative and do not treat the problem.	pdt	Read Full Thread Reply
01/8/2017 20:45	I see the RVC has put out a press release in respect of getting grant funding for a 4 year PhD study into osteoarthritis using SFX-01 hTTp://www.rvc.ac.uk/news-and-events/rvc-news/royal-veterinary-college-and-evgen-pharma-secure-funding-to-explore-treatment-for-osteoarthritis Four years seems like a long time but hopefully there will be periodic updates.	pdt	Read Full Thread Reply
29/7/2017 17:23	timbo and paxman Thanks for posting links and comments, all very interesting and positive. I can see lots of people knocking on the Evgen door wanting to run collaborative trials over the coming months in all sorts of indications. They are a small team so hopefully it doesn't distract them from their key focus.	pdt	Read Full Thread Reply
29/7/2017 14:03	My guess is of today Evgen have things covered pretty tight on a pharma grade compound which would meet FDA dosage rules consistently. e.g. here's a 2015 Slideshare from a member of the US's NIH addressing DMD: hTTps://www.slideshare.net/JordanGladman/gladman-nrf2-dmd Check out the last 2 pages - 'Next Steps' - collaborate with Evgen. Don't remember Evgen mentioning DMD.	paxman	Read Full Thread Reply
29/7/2017 11:56	>>>>PDT Yes, that seems to confirm that other related compounds are likely to have similar activity which helps validate Evgen's decision to license a series of homologous compounds from The University of Seville back in November 2015 (in exchange for a small royalty ≤ 1%): https://www.investegate.co.uk/evgen-pharma-plc--evg-/rns/expands-pipeline-with-novel-compounds/201511230700055309G/ Whilst looking for the John Hopkins University ASD application (see previous post), I came across what I suspect is the patent application concerning the Saville University compounds now licensed to Evgen: https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=2015110863A1&KC=A1&FT=D&ND=3&date=20150423&DB=&locale=en_EP#	timbo003	Read Full Thread Reply
28/7/2017 16:44	Not convinced they'd have to talk to John Hopkins. Surely John Hopkins could only patent their method of storing or freezing or delivering or measuring sulforaphane, a naturally occurring molecule. SFX-01 won't need similar storage etc. Any attempt to patent human body processes would fail. Besides there's too much prior art ( research) in sulforaphane. IMHO only synthetic chemical compositions, e.g. SFX-01, are likely to be granted. I see a JH patent application in 2012 but not granted to date. Evgen are quite rightly screening loads of analogues and no doubt patenting the most promising.	paxman	Read Full Thread Reply
28/7/2017 10:12	Thanks timbo003 - your graphs are easier to interpret than the black and white ones on page 32 of the AGM presentation.	paxman	Read Full Thread Reply
28/7/2017 10:07	What I like is the minimal placebo effect, so any SFX-01 effect in a phase 2 should hopefully be easy to segregate. Also the reversion to pre treatment status when sulforaphane is no longer taken suggests genuine efficacy. Interesting results. I think current drugs used for autism are symptom reducers. Taking autism prevalence off the internet - about 1% of the global population - 70 million - and taking a quick look at the above data - 50% of users have a more than 20% reduction in symptoms - suggests a very large market. Hope Evgen raise some more money and accelerate all these phase 2 indications trials.	paxman	Read Full Thread Reply

Chat Pages: 20 19 18 17 16 15 14 13 12 11 10 9 Older

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.